Speciality Medicines IPO Details: Price, Listing Date, Lot Size & Review

What is the Speciality Medicines IPO?

Speciality Medicines IPO is a book-built issue worth ₹29.14 crores, comprising entirely of a fresh issue of shares. This means no existing shareholders are offloading their stake — all proceeds will go directly to the company for business purposes.

The IPO is listed on the BSE SME platform, targeting investors who want early exposure to a fast-growing speciality pharmaceuticals distribution company.

Speciality Medicines IPO Price Band

The Speciality Medicines IPO price band is set between ₹117 and ₹124 per share. Investors can bid at any price within this range, though most prefer bidding at the upper price band (₹124) to maximise their chances of allotment.

The face value of each share is ₹10, making the premium over face value quite significant — reflecting the company's growth trajectory and market positioning.

Speciality Medicines IPO Listing Date

The Speciality Medicines IPO listing date is tentatively set as Monday, March 30, 2026, on the BSE SME exchange. The allotment is expected to be finalised on March 25, 2026, and shares will be credited to demat accounts by March 27, 2026.

Investors should keep an eye on the grey market premium (GMP) in the days leading up to listing, as it can often indicate expected listing gains.

About Speciality Medicines Limited

Incorporated in 2021, Speciality Medicines Limited is a relatively young but fast-growing company engaged in the marketing and distribution of finished pharmaceutical formulations. The company focuses on speciality medicines used in the treatment of complex chronic conditions — including high-cost oral and injectable medications used in therapeutic areas such as oncology, immunology, neurology, and rare diseases.

Product Portfolio

The company offers a diverse range of dosage forms, including:

• Tablets, capsules, and syrups

• Injections and infusions

• Inhalers and nasal sprays

• Creams, gels, and ointments

• Eye drops and ophthalmic solutions

• Oral solutions, sachets, and suspensions

As of March 31, 2025, the company's portfolio includes more than 900 products across multiple therapeutic categories.

Business Models

Speciality Medicines operates through two integrated business models:

• Contract Manufacturing: Finished formulations are manufactured through third-party manufacturers in India for international distribution.

• Marketing & Distribution: The company sources speciality pharmaceutical products from manufacturers and handles procurement, warehousing, and wholesale supply to healthcare providers and retailers.

Global Presence

Despite being incorporated only in 2021, the company has built a notable international footprint:

• Distribution network across more than 20 states in India

• Operations in more than 35 countries worldwide, including markets in Asia, Africa, Europe, and the Middle East

• Registered products in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia

• As of February 28, 2026: 7 products registered overseas and 54 products in the registration pipeline across 5 countries

Competitive Strengths

Speciality Medicines Limited highlights the following as its core competitive advantages:

• Diversified Global Presence: Revenue is generated from 35+ countries, reducing dependence on any single geography.

• Diversified Product Portfolio: A portfolio of 900+ products across multiple therapeutic categories and dosage forms.

• Long-Standing Client Relationships: Growing client base with repeat orders — nine clients generated revenue above ₹1 Cr in FY25, up from five in FY23.

• Experienced Promoters and Management: Led by MD/CEO Mr. Parth Goyani.

• Quality Assurance: The company holds ISO 9001:2015 certification and works with third-party manufacturers who hold the required regulatory accreditations.

Key Risks to Consider

Before investing, here are some important risk factors:

• One of the company's promoters faces an ongoing criminal proceeding related to the Drugs and Cosmetics Act and the Essential Commodities Act, currently pending before the Gujarat High Court.

• The company is dependent on a limited number of customers — the top 5 customers contributed over 60% of revenue in FY25.

• Negative operating cash flows have been reported in FY23, FY24, and FY25.

• Heavy reliance on third-party manufacturers for product supply.

• Significant portion of revenue comes from exports, exposing the company to international trade and regulatory risks.

Should You Apply for the Speciality Medicines IPO?

The Speciality Medicines IPO presents an interesting opportunity in the BSE SME space, backed by strong revenue growth, a diversified product portfolio, and a growing international presence. The PAT growth of nearly 3x in FY25 is an encouraging sign.

However, the high minimum investment (₹2,48,000 for retail), negative operating cash flows, and the pending legal matter involving a promoter are factors that should give investors pause. As with any SME IPO, the risks are higher and liquidity post-listing may be more limited compared to mainboard IPOs.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Please consult a registered financial advisor before making investment decisions. Investments in IPOs are subject to market risks.

Speciality Medicines IPO — Quick Summary

• IPO Dates: March 20–24, 2026

• Speciality Medicines IPO Price: ₹117–₹124 per share

• Lot Size: 1,000 shares (Minimum 2 lots for retail)

• Minimum Investment: ₹2,48,000

• Speciality Medicines IPO Listing Date: March 30, 2026

• Listing Exchange: BSE SME

• Issue Size: ₹29.14 Crores (100% Fresh Issue)

Stay updated with the latest IPO news, allotment status, and listing day performance only on ultra, your go-to platform for smart investing insights at ultra.